Live search
TopFind is fetching the latest matches for your search.
We reviewed 15 live results for trazimera trastuzumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Source: Pfizer Philippines Inc.
Description
Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022.
Best for
HER2 Positive breast cancer, Stomach cancer and Targeted oncology therapy
Rating
Source: Amgen
Description
Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product.
Best for
Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer and Hospital Administered oncology
Rating
Source: Amgen
Description
Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies.
Best for
HER2 Positive cancer patients, Breast cancer treatment, Gastric adenocarcinoma patients and Oncology biosimilar cost Savings
Rating
| Compare | Trazimera (Trastuzumab) | Kanjinti (Trastuzumab) 440 mg/vial | Kanjinti (Trastuzumab) 150 mg/vial |
|---|---|---|---|
| Source | Pfizer Philippines Inc. | Amgen | Amgen |
| Description | Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022. | Kanjinti is a high-dose 440 mg formulation of the trastuzumab biosimilar, indicated for patients with HER2-positive breast and gastric cancers. It works as a monoclonal antibody that inhibits the growth of tumor cells overexpressing the HER2 protein. Administered only by intravenous infusion, this prescription medication is registered in Singapore (SIN16207P) and is used in both early and metastatic stages of cancer therapy. The product is a biological medicine developed to meet the same quality, safety, and efficacy standards as the reference product. | Kanjinti is a biosimilar monoclonal antibody to the reference medicine Herceptin (trastuzumab). As a HER2/neu receptor antagonist, it is used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. This 150 mg powder for injection vial is a prescription-only medicine (POM) typically administered via intravenous infusion in a clinical setting. It is registered in Singapore by the Health Sciences Authority (HSA) and listed in the National Drug Formulary for potential medical subsidies. |
| Best for | HER2 Positive breast cancer, Stomach cancer and Targeted oncology therapy | Metastatic breast cancer, High Dose trastuzumab therapy, HER2 Positive gastric cancer and Hospital Administered oncology | HER2 Positive cancer patients, Breast cancer treatment, Gastric adenocarcinoma patients and Oncology biosimilar cost Savings |
| Action | |||
| Rating |
If you want the most balanced option to start with, I recommend:
"Trazimera (Trastuzumab) from Pfizer Philippines Inc.."
I picked this because Trazimera is a recently approved, high-standard biosimilar for targeted HER2-positive cancer therapy.